SAFETY AND TOLERABILITY OF LEVOSULPIRIDE IN THE PREVENTION OF GASTRIC FEED INTOLERANCE IN ICU PATIENTS

Rahul Sharma, Rupesh Choudhary, Divya Drishti* and Ankita Jamwal

ABSTRACT

Background: The objective of this study was to assess the effectiveness and safety of levosulpiride in patients with dysmotility-like functional dyspepsia including nonerosive reflux esophagitis in conditions of daily practice. Dysmotility-like functional dyspepsia is a condition characterized by delayed gastric emptying and a sense of fullness. Non-erosive reflux disease is a condition where patients experience symptoms of gastroesophageal reflux disease without evidence of esophageal mucosal injury. Method: The study aimed to evaluate the safety and tolerability of levosulpiride in preventing gastric feed intolerance in ICU patients. The trial was a prospective, open-label, single-arm study involving 50 ICU patients receiving levosulpiride at a dose of 25 mg three times a day for five days. The results showed that levosulpiride was well tolerated, with no serious adverse events reported, and was effective in preventing gastric feed intolerance in ICU patients. Results: Levosulpiride was found to significantly decrease dyspeptic symptoms and was well-tolerated in patients with dysmotility-like functional dyspepsia and non-erosive reflux disease. Conclusion: Levosulpiride is an effective and safe treatment for dysmotility-like functional dyspepsia and non-erosive reflux disease, demonstrating a significant decrease in symptoms and no study abandonment due to adverse events.

Keywords: Levosulpiride, Dysmotility-like functional dyspepsia, Non-erosive reflux disease, Treatment efficacy.